- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Idiopathic multicentric Castleman’s disease (iMCD)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 2255KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 879KB)
Siltuximab – July 2021
Siltuximab: Powder for injection 100 mg, Powder for injection 400 mg; Sylvant®
Last updated
12 November 2021